Immunosuppressants - PDFSEARCH.IO - Document Search Engine

Immunosuppressants
Results: 1821

#	Item
601	Microsoft PowerPoint - A Case Study Using the BRAT Framework and Quantitative Methods for Benefit-Risk Assessment - Final 20131 Add to Reading List Source URL: www.amstat.org Language: English - Date: 2013-11-12 00:22:34 Risk management Immunosuppressants Natalizumab Actuarial science Progressive multifocal leukoencephalopathy Innovative Medicines Initiative European Federation of Pharmaceutical Industries and Associations Risk Ethics Management
602	1 SUPPLEMENTAL MATERIALS 2 Add to Reading List Source URL: ard.bmj.com Language: English - Date: 2014-08-30 01:12:35 Immunosuppressants Organochlorides Quinolines Intensive care medicine Leflunomide Organofluorides Disease-modifying antirheumatic drug Tocilizumab Hydroxychloroquine Medicine Health Chemistry
603	The Role of Biologic Therapies in Emerging Infections Session 13: Health Care Associated Emerging Infections November 2, 2014 John W. Baddley, MD, MSPH University of Alabama at Birmingham Add to Reading List Source URL: imed.isid.org Language: English - Date: 2014-12-02 17:19:45 Pharmacology Chronic obstructive pulmonary disease Smoking Infliximab Hepatitis Health Immunosuppressants Medicine
604	35 Management of Low-cost Drugs and Equipment Carine Werder THE DRUG MANAGEMENT CYCLE Add to Reading List Source URL: www.glowm.com Language: English - Date: 2010-12-31 19:00:00 Organic chemistry Piperazines Otologicals Immunosuppressants Organofluorides Pefloxacin Ciprofloxacin Adverse effect Antidepressant Pharmacology Chemistry Medicine
605	Volume[removed]Editor: Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Contents - Glatiramer Add to Reading List Source URL: dpic.org Language: English - Date: 2014-11-10 15:46:28 Multiple sclerosis Cytokines Glatiramer acetate Autoimmune diseases Immunosuppressants Interferon beta-1a Natalizumab Placebo Neuromyelitis optica Medicine Immunology Health
606	An Independent Licensee of the Blue Cross and Blue Shield Association Prior Authorization Requirements Effective: [removed] Add to Reading List Source URL: www.azbluemedicare.com Language: English - Date: 2014-11-26 15:58:03 Biology Anemia Leflunomide Etanercept Erythropoietin Disease-modifying antirheumatic drug Infliximab Anakinra Rheumatoid arthritis Medicine Immunosuppressants Pharmacology
607	What’s “hot” about thermogenic agents Add to Reading List Source URL: dpic.org Language: English - Date: 2014-11-10 15:46:29 Immunosuppressants Autoimmune diseases Natalizumab Cytokines Multiple sclerosis Progressive multifocal leukoencephalopathy JC virus Rituximab Interferon beta-1a Medicine Health Immunology
608	November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I Add to Reading List Source URL: files.shareholder.com Language: English Medicine Immunosuppressants Macrolides Atopic dermatitis Regeneron Eczema Pharmacology Dermatitis Atopy Health Type 1 hypersensitivity Immune system
609	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ILARIS safely and effectively. See full prescribing information for ILARIS. ILARIS (canakinumab) injection for subcu Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2014-10-17 09:51:37 Canakinumab Novartis IL1B Medicine Immune system Organofluorides Monoclonal antibodies Anakinra Flucytosine Immunosuppressants Cytokines Pharmacology
610	2013 Business Highlights Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the relaunch and strength of key brands in our U.S. over-the-counter (OTC) an Add to Reading List Source URL: 2013annualreport.jnj.com Language: English - Date: 2014-03-07 15:21:20 Centocor Health Monoclonal antibodies Johnson & Johnson Golimumab Ustekinumab Synthes Infliximab Biologic Pharmacology Medicine Immunosuppressants

UPDATE